Transient Detection of Chlamydial-Specific Th1 Memory Cells in the Peripheral Circulation of Women with History of Chlamydia trachomatis Genital Tract Infection
Article first published online: 31 AUG 2012
© 2012 John Wiley & Sons A/S
American Journal of Reproductive Immunology
Volume 68, Issue 6, pages 499–506, December 2012
How to Cite
Transient detection of chlamydial-specific Th1 memory cells in the peripheral circulation of women with history of Chlamydia trachomatis genital tract infection. Am J Reprod Immunol 2012; 00: 00–00, , , , , , .
- Issue published online: 8 NOV 2012
- Article first published online: 31 AUG 2012
- Manuscript Accepted: 24 JUL 2012
- Manuscript Received: 16 MAR 2012
- University of Pittsburgh's Departments of Obstetrics, Gynecology and Reproductive Sciences and Pediatrics
- National Institute of Allergy and Infectious Diseases. Grant Number: U19AI084024
- Chlamydia trachomatis;
- peripheral blood mononuclear cells
Development of safe and effective Chlamydia trachomatis vaccines requires better understanding of the host immune responses elicited by natural infection.
Method of study
Peripheral blood mononuclear cells isolated from women with or without history of genital tract chlamydial infection were stimulated with inactivated C. trachomatis elementary bodies (EB) in ELISPOT assays that enumerated frequencies of cells producing interferon (IFN)-γ or interleukin (IL)-17.
IFN-γ-positive cells were highest among women sampled 30–60 days after diagnosis of C. trachomatis infection and treatment initiation, while the numbers of IFN-γ-positive cells were equally low among uninfected women and women sampled <30 or >60 days after diagnosis of infection. Conversely, IL-17-positive cell numbers were uniformly low among all participants.
Dramatically reduced numbers of Chlamydia-specific Th1 memory cells in the peripheral circulation of study participants sampled more than 2 months after diagnosis, and initiation of treatment provides new insight into the results from C. trachomatis vaccine trials, in which immunization with EB provided only short-lived protection. Our results also suggest that an effective vaccine against this weakly antigenic intracellular pathogen will need to generate immunological memory more durable than that elicited by natural infection.